IRF4 Antibodies

Structure of IRF4

IRF4 is a transcription factor protein with a molecular weight of approximately 52 kDa. Its precise molecular weight varies slightly among different species due to differences in amino acid sequences.

This protein is composed of 451 amino acids, forming a characteristic helical - angular - helical DNA-binding domain. Its core functional structure includes an N-terminal DNA binding domain capable of recognizing specific interferon sequence response elements, as well as a C-terminal IRF association domain for mediating interactions with other transcription factors to regulate immune gene expression. Its tertiary structure forms a stable dimer, which is crucial for its precise identification of target gene promoters and the performance of transcriptional regulatory functions.

Fig. 1 Schematic diagram of IRF4 structure.¹

Key structural properties of IRF4:

• Contains N end dna-binding domain structure and C end IRF correlation domain
• DNA binding domain the typical spiral - corner - spiral fold pattern
• Key domains form stable functional dimer interfaces

Functions of IRF4

The core function of the IRF4 transcription factor is to regulate the differentiation and activation of immune cells, and it is also involved in a wide range of physiological and pathological processes such as the cell cycle, apoptosis and tumorigenesis.

IRF4 precisely regulates the transcriptional activity of its target genes by forming complexes with other transcription factors. This characteristic enables it to fine-tune immune responses based on different cellular signals. The fine regulation of its expression level and activity is of core significance for maintaining the immune homeostasis of the body.

Applications of IRF4 and IRF4 Antibody in Literature

1. Wong, Regina Wan Ju, et al. "IRF4 as an oncogenic master transcription factor." Cancers 14.17 (2022): 4314. https://doi.org/10.3390/cancers14174314

The article indicates that IRF4 is a member of the interferon regulatory factor family and plays a key role in the normal development of lymphocytes. When it is abnormally expressed, IRF4 can activate oncogenes such as MYC by forming regulatory circuits with factors like NF-κB, thereby driving the occurrence and development of various mature lymphoid tumors.

2. Maffei, Rossana, et al. "The dynamic functions of IRF4 in B cell malignancies." Clinical and Experimental Medicine 23.4 (2023): 1171-1180. https://doi.org/10.1007/s10238-022-00968-0

The article indicates that IRF4 is a key regulatory factor in B cell development and malignancy. Through the "dynamic control" mechanism, it activates distinct genetic programs at different expression levels, playing a dual role of tumor suppression and cancer promotion. This article summarizes the pathogenic mechanism and potential therapeutic strategies of IRF4 in B-cell tumors such as multiple myeloma.

3. Lu J, Liang T, et al. "Regulatory effects of IRF4 on immune cells in the tumor microenvironment." Frontiers in immunology 14 (2023): 1086803. https://doi.org/10.3389/fimmu.2023.1086803

The article indicates that IRF4 is a key regulatory factor in the tumor microenvironment (TME), dominating the differentiation and function of immune cells such as T cells. It can not only drive immune responses but also participate in the process of T cell depletion. Therefore, targeting IRF4 is expected to reverse T cell exhaustion and improve TME, thus becoming a new direction in tumor immunotherapy.

4. Thouenon, Romane, and Sven Kracker. "Human inborn errors of immunity associated with IRF4." Frontiers in Immunology 14 (2023): 1236889. https://doi.org/10.3389/fimmu.2023.1236889

The article indicates that IRF4 is a key transcription factor of adaptive immunity. Its deficiency or haploid insufficiency can lead to congenital immune errors (IEI), causing cellular immune deficiency accompanied by agammaglobulinemia and other diseases. This article focuses on reviewing the pathogenic mechanism of IRF4 and the related clinical manifestations of IEI.

5. Harrer, Dennis Christoph, et al. "IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities." Frontiers in Immunology 14 (2023): 1185618. https://doi.org/10.3389/fimmu.2023.1185618

Studies have shown that down-regulating IRF4 through shRNA can significantly enhance the persistent anti-tumor ability of CAR-T cells. CAR-T cells with decreased IRF4 levels can delay functional exhaustion, enhance sensitivity to low-antigen cancer cells, and upregulate CD27 under long-term and repeated antigen stimulation, thereby achieving better long-term tumor control.

Creative Biolabs: IRF4 Antibodies for Research

Creative Biolabs specializes in the production of high-quality IRF4 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom IRF4 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our IRF4 antibodies, custom preparations, or technical support, contact us at email.